Looking to learn how Kleeman et al. used iPRECIO implantable, programmable and refillable pumps and ALZET LLC’s osmotic pump in their recent publication in Nature which was published 25th March 2026?

Kleeman, S. O., Michalski, K., Zhao, X., Steigerwald, R., Ferrer, M., Levett, L., ... & Janowitz, T. (2026). Ectopic NMDAR expression in cancer unmasks germline-encoded autoimmunity. Nature, 1-13.
https://www.nature.com/articles/s41586-026-10278-0

Want to learn more about the capabilities of iPRECIO Programmable Pumps via highlights from Peer Reviewed publications? Our updated eBook is available now. Includes our latest on-demand webinar and slide deck details from Dr. Jamie Oliver, Chief Medical Officer of Starton Therapeutics available on Labroots. Results from 3 different studies with iPRECIO pumps were shared in the webinar. Contact us directly via email, Contact Us Form or download from Linkedin. We are to help.

Want to learn more about the capabilities of iPRECIO Programmable Pumps via highlights from Peer Reviewed publications? Our updated eBook is available now. Contact us directly via email, Contact Us Form or download from Linkedin. We are to help.

Benson et al. (2026) addressed a potential circadian confound – the time of day when infusion pumps were implanted – by using programmable iPRECIO pumps to standardize drug delivery timing across subjects, illustrating a proactive approach to experimental design

Benson, Lance N., et al. "Time of Day Drives Angiotensin II–Dependent Hypertension."
Hypertension 83.2 (2026): e25906.
https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25906
https://pmc.ncbi.nlm.nih.gov/articles/PMC12826273/

Slide deck from Dr. Jamie Oliver, Chief Medical Officer of Starton Therapeutics available on Labroots. Results from 3 different studies with iPRECIO pumps were shared in the webinar.

Latest peer-reviewed publications from our users highlight how iPRECIO programmable pumps enable complex dosing regimens and consistent exposure profiles in free-moving subjects.